Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas patients who only inherited one gene encoding for abnormal HbS and a different ...
Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...
Researchers found higher C-reactive protein levels during the follicular phase in women with sickle cell disease, indicating cycle-linked inflammation shifts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results